Global Syndromic Multiplex Diagnostics Market Report 2024: Unveiling the Future of Infectious Disease Diagnostics with Regional Projections by Syndrome
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts. Strategies and Trends, Forecasts by Syndrome (Respiratory, Sepsis, GI Etc.), by Country, with Market Analysis, Executive Guides and Customization" report has been added to * ResearchAndMarkets.com's* offering.
The emergence of the COVID-19 pandemic has accelerated advancements and growth within the syndromic multiplex diagnostic markets, signaling a paradigm shift in infectious disease diagnostics. A new comprehensive report now available provides critical insights into this rapidly evolving market, spotlighting the influence of COVID-19 impacts and prospective expansion rates.
Syndromic Multiplex Diagnostic technologies are at the forefront of a breakthrough, presenting data that suggest the potential to redefine conventional approaches to infectious disease testing. This report meticulously explores the market trends, strategies, and projections by syndrome, including respiratory, sepsis, gastrointestinal, and more, taking a granular look at the diagnostic landscape country-by-country.
The integration of Point of Care Testing and Molecular Diagnostics is transforming clinical practices, potentially rendering targeted tests for specific pathogens less relevant. Innovations within this sector suggest diagnostic procedures might not only occur within medical facilities but also extend to the Physician's Office and the patient's home. The intersection of improved healthcare outcomes, cost reduction, and the fight against antimicrobial resistance is a vital theme of this report.
· The report details the shifting dynamics of infectious disease diagnostics in the age of COVID-19
· It demonstrates how syndromic multiplex diagnostics offer solutions with increased efficiency and effectiveness
· Market forecasts for the next five years outline potential growth and investment opportunities
· The evolving role of diagnostics in patient care management and its impact on traditional testing methods are analyzed
The document delves into the factors propelling market expansion, with a special section focusing on how syndromic molecular diagnostics is taking precedence over traditional panel-based testing for infectious diseases. In a rapidly changing healthcare environment, informed decision-making is more critical than ever. This report serves as a valuable resource for stakeholders looking to understand the intricacies of the syndromic multiplex diagnostic markets and their trajectory in the post-pandemic era.
Experts and industry leaders have now access to vital analysis and projections that will shape strategic planning and response to current and future healthcare challenges.
*Remarkable Developments in the Infectious Disease Diagnostic Market*
The medical community continues to witness remarkable developments in the infectious disease diagnostic market, driven by technological innovations and an urgent need for rapid and accurate diagnostics spurred by the pandemic. Syndromic multiplex diagnostics is at the cusp of revolutionizing this domain, offering comprehensive insights and a future outlook for stakeholders worldwide.
*Companies Mentioned*
· Abacus Diagnostica
· Abbott Diagnostics
· Accelerate Diagnostics
· Ador Diagnostics
· Akonni Biosystems
· Alveo Technologies
· Antelope Dx
· Applied BioCode
· Aus Diagnostics
· Baebies
· Beckman Coulter Diagnostics
· Becton, Dickinson and Company
· Binx Health
· Bio-Rad Laboratories, Inc
· Biocartis
· BioFire Diagnostics (bioMérieux)
· bioMérieux Diagnostics
· Bosch Healthcare Solutions GmbH
· Cepheid (Danaher)
· Credo Diagnostics Biomedical
· Cue Health
· Curetis N.V./Curetis GmbH
· Diagenode Diagnostics
· Diasorin S.p.A.
· Enzo Life Sciences, Inc.
· Eurofins Scientific
· Fluxergy
· Fusion Genomics.
· Genetic Signatures
· GenMark Dx (Roche)
· Hibergene Diagnostics
· Hologic
· Immunexpress
· Inflammatix
· Invetech
· Janssen Diagnostics
· Karius
· Lexagene
· LightDeck Diagnostics
· Lucira Health
· Luminex Corp
· Maxim Biomedical
· Meridian Bioscience
· Mesa Biotech (Thermo Fisher)
· Millipore Sigma
· Mobidiag (Hologic)
· Molbio Diagnostics
· Nanomix
· Novel Microdevices
· Operon
· Oxford Nanopore Technologies
· Panagene
· Perkin Elmer
· Primerdesign (Novacyt)
· Prominex
· Qiagen Gmbh
· Quantumdx
· Quidel
· Roche Molecular Diagnostics
· Saw Diagnostics
· Seegene
· Siemens Healthineers
· Sona Nanotech
· SpeeDx
· T2 Biosystems
· Talis Biomedical
· Thermo Fisher Scientific Inc.
· Veramarx
· Visby Medical
· XCR Diagnostics
For more information about this report visit https://www.researchandmarkets.com/r/fujel3
*About ResearchAndMarkets.com*
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900